YCC Entrepreneurs
Over the past 20 years, Yale inventions have led to the creation of nearly 60 companies in the New Haven region that have attracted more than $1 billion of professional venture capital investment and have created over 1,400 jobs in the region. Many of these local companies are focused on oncology drug development based on science from Yale Cancer Center members, including:
Companies
Arvinas
Research Program: Developmental Therapeutics
Arvinas is a pharmaceutical company focused on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases.
Cybrexa Therapeutics
Research Program: Radiobiology & RadiotherapyResearch Program: Radiobiology & Radiotherapy
Cybrexa Therapeutics is an oncology-focused biotechnology company developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment.Immunova
Research Program: Developmental Therapeutics
Immunova Pharmaceuticals has a proprietary Nanolipogel™ platform to deliver desired combinations of drugs in nanoparticle formulations to the disease microenvironment.
Isoplexis
Research Program: Cancer Signaling Networks
IsoPlexis is transforming precision oncology in cell and cancer immunotherapy by defining the complete function of each cell for the first time.
Kleo Pharmaceuticals
Research Program: Developmental Therapeutics
Kleo Pharmaceuticals is pioneering a new class of immunotherapies utilizing small molecules to activate an individual’s own immune system to fight against cancers and infectious diseases.
Celldex Therapeutics
Research Program: Cancer Signaling Networks
Celldex Therapeutics acquired Kolltan Pharmaceuticals. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
Modulate Therapeutics
Research Program: Developmental Therapeutics
Modulate Therapeutics is a special purpose company created to develop one compound, IMM-01, to proof-of-concept.
Navigate
Research Program: Cancer Signaling Networks
Navigate (formally HistoRx) is developing novel diagnostic solutions to help turn innovative cancer treatment ideas into reality.
Next Cure
Research Program: Cancer Immunology
NextCure is focused on discovering and developing next generation immunotherapy-based biologics for cancer and other immune-related disorders.
Onyx Pharmaceuticals
Research Program: Developmental Therapeutics
Proteolix/Acquired by Onyx Pharma and develops and markets medicines for the treatment of cancer.Vedanta Biosciences
Research Program: Cancer Immunology
Vedanta Biosciences is using its proprietary platform to discover and develop a novel class of drugs that modulate pathways of interaction between the human microbiome and the host immune system to treat disease.
Osmol Therapeutics
Research Program: Developmental Therapeutics
Osmol Therapeutics is developing a therapy for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN) and Neurologic Impairment.
Patrys
Research Program: Radiobiology & RadiotherapyResearch Program: Radiobiology & Radiotherapy
Nucleus Therapeutics/Acquired by Patrys is focused on the development of antibody therapies for major market opportunities in the oncology area.
Phlip
Research Program: Developmental Therapeutics
pHILiP Inc. is focused on detecting, targeting, and treating acidic diseased tissue using selective insertion and folding of membrane peptides, primarily in oncology.
PhytoCeutica
Research Program: Developmental Therapeutics
PhytoCeutica develops herbal therapeutics for cancer and was acquired by Kadmon Pharmaceuticals.Vyriad
Research Program: Cancer Microbiology
Omnis Pharmaceuticals- merged to form Vyriad and is a clinical stage biotechnology company dedicated to delivering groundbreaking virus-based therapies for cancer patients.
Vedanta Biosciences
Research Program: Cancer Immunology
Vedanta Biosciences is using its proprietary platform to discover and develop a novel class of drugs that modulate pathways of interaction between the human microbiome and the host immune system to treat disease.
Yiviva
Research Program: Developmental Therapeutics
Yiviva is a biotechnology company to develop evidence-based botanical products to address aging-associated diseases.